Data Sheet (Cat.No.T36841)

IPI-9119

Chemical Properties



CAS No. : 1346564-56-4

Formula: C24H19F2N5O5

Molecular Weight: 495.43

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	IPI-9119 is an orally active, selective, and irreversible FASN inhibitor (IC50 = 0.3 nM).
Targets(IC50)	Fatty Acid Synthase
In vitro	IPI-9119 (0.05, 0.1, 0.25, 0.5, 5 μM; 6 days) inhibits AR-FL and AR-V7 protein expression. IPI-9119 (0.1, 0.5 μM; 6 days) inhibits cell growth and induces cell cycle arrest and apoptosis[1]. IPI-9119 inhibits FASN in cellular occupancy assays (IC5010nM) and shows more than 400-fold selectivity against several additional serine hydrolases[2].
In vivo	IPI-9119 inhibits tumor growth of castration-resistant prostate cancer in xenografts mouse models[1].

Solubility Information

Solubility	DMSO: 95 mg/mL (191.75 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (6.66 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.0184 mL	10.0922 mL	20.1845 mL
5 mM	0.4037 mL	2.0184 mL	4.0369 mL
10 mM	0.2018 mL	1.0092 mL	2.0184 mL
50 mM	0.0404 mL	0.2018 mL	0.4037 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Giorgia Zadra, et al. Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2019 Jan 8;116(2):631-640.
Erin Broph, et al. Abstract 1891: Pharmacological target validation studies of fatty acid synthase in carcinoma using the potent, selective and orally bioavailable inhibitor IPI-9119.